{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:59Z","timestamp":1787243399727,"version":"build-2736575974"},"reference-count":60,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023,12,26]]},"DOI":"10.3960\/jslrt.23037","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T17:12:26Z","timestamp":1703524346000},"page":"230-239","source":"Crossref","is-referenced-by-count":5,"title":["Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma"],"prefix":"10.3960","volume":"63","author":[{"given":"Makka","family":"Adam","sequence":"first","affiliation":[{"name":"Department of Microbial, Cellular and Molecular Biology, College of Natural Sciences, Addis Ababa University, Addis Ababa, Ethiopia,"},{"name":"Armauer Hansen Research Institute, Addis Ababa, Ethiopia,"},{"name":"Department of Oncology, Faculty of Medicine, Lund University, Lund, Sweden,"},{"name":"Yirgalem Hospital Medical College, Yirgalem, Ethiopia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Bekuretsion","sequence":"additional","affiliation":[{"name":"Department of Pathology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amha","family":"Gebremedhin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kwiecinska","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawleigh","family":"Howe","sequence":"additional","affiliation":[{"name":"Armauer Hansen Research Institute, Addis Ababa, Ethiopia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyene","family":"Petros","sequence":"additional","affiliation":[{"name":"Department of Microbial, Cellular and Molecular Biology, College of Natural Sciences, Addis Ababa University, Addis Ababa, Ethiopia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, Lund University, Lund, Sweden,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004; 350: 1328-1337.","DOI":"10.1056\/NEJMra032015"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Fitzmaurice C, Allen C, Barber RM <i>et al.<\/i> Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017; 3: 524-548.","DOI":"10.1001\/jamaoncol.2016.5688"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Biggar RJ, Henle W, Fleisher G <i>et al.<\/i> Primary Epstein-Barr virus infections in African infants. I. Decline of maternal antibodies and time of infection. Int J Cancer. 1978; 22: 239-243.","DOI":"10.1002\/ijc.2910220304"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000; 343: 481-492.","DOI":"10.1056\/NEJM200008173430707"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Gopal S, Wood WA, Lee SJ <i>et al.<\/i> Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood. 2012; 119: 5078-5087.","DOI":"10.1182\/blood-2012-02-387092"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 2009; 143: 209-221.","DOI":"10.1016\/j.virusres.2009.07.005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin\u2019s lymphoma. Ann Oncol. 2002; 13: 147-152.","DOI":"10.1093\/annonc\/mdf652"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Dinand V, Dawar R, Arya LS <i>et al.<\/i> Hodgkin\u2019s lymphoma in Indian children: prevalence and significance of Epstein\u2013Barr virus detection in Hodgkin\u2019s and Reed\u2013Sternberg cells. Eur J Cancer. 2007; 43: 161-168.","DOI":"10.1016\/j.ejca.2006.08.036"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Glaser SL, Lin RJ, Stewart SL <i>et al.<\/i> Epstein-Barr virus-associated Hodgkin\u2019s disease: epidemiologic characteristics in international data. Int J Cancer. 1997; 70: 375-382.","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.3.CO;2-L"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Chang KC, Chen PCH, Jones D, Su IJ. Changing patterns in the frequency of Hodgkin lymphoma subtypes and Epstein\u2013Barr virus association in Taiwan. Cancer Sci. 2008; 99: 345-349.","DOI":"10.1111\/j.1349-7006.2007.00667.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Al-Salam S, John A, Daoud S, Chong SM, Castella A. Expression of Epstein\u2013Barr virus in Hodgkin lymphoma in a population of United Arab Emirates nationals. Leuk Lymphoma. 2008; 49: 1769-1777.","DOI":"10.1080\/10428190802270894"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Castillo JJ, Beltran BE, Miranda RN <i>et al.<\/i> Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011; 16: 87-96.","DOI":"10.1634\/theoncologist.2010-0213"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Mwakigonja AR, Kaaya EE, Heiden T <i>et al.<\/i> Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV\/EBV association. BMC Cancer. 2010; 10: 344.","DOI":"10.1186\/1471-2407-10-344"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kusuda M, Toriyama K, Kamidigo NO, Itakura H. A comparison of epidemiologic, histologic, and virologic studies on Hodgkin\u2019s disease in western Kenya and Nagasaki, Japan. Am J Trop Med Hyg. 1998; 59: 801-807.","DOI":"10.4269\/ajtmh.1998.59.801"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Moskowitz CH, Ribrag V, Michot JM <i>et al.<\/i> PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood. 2014; 124: 290.","DOI":"10.1182\/blood.V124.21.290.290"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Ansell SM, Lesokhin AM, Borrello I <i>et al.<\/i> PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015; 372: 311-319.","DOI":"10.1056\/NEJMoa1411087"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011; 29: 1812-1826.","DOI":"10.1200\/JCO.2010.32.8401"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ansell S. Novel agents in the therapy of Hodgkin lymphoma. Am Soc Clin Oncol Educ Book. 2015; 35: e479-e482.","DOI":"10.14694\/EdBook_AM.2015.35.e479"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Marshall NA, Christie LE, Munro LR <i>et al.<\/i> Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004; 103: 1755-1762.","DOI":"10.1182\/blood-2003-07-2594"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Greaves P, Clear A, Owen A <i>et al.<\/i> Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood. 2013; 122: 2856-2863.","DOI":"10.1182\/blood-2013-06-508044"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Wu R, Sattarzadeh A, Rutgers B <i>et al.<\/i> The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein\u2013Barr virus presence and location within the tumor. Blood Cancer J. 2016; 6: e417.","DOI":"10.1038\/bcj.2016.26"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Poppema S, van den Berg A, Interaction between host T cells and Reed\u2013Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol. 2000; 10: 345-350.","DOI":"10.1006\/scbi.2000.0327"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Schreck S, Friebel D, Buettner M <i>et al.<\/i> Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009; 27: 31-39.","DOI":"10.1002\/hon.878"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Wherry EJ, Ha SJ, Kaech SM <i>et al.<\/i> Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007; 27: 670-684.","DOI":"10.1016\/j.immuni.2007.09.006"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Ahmadzadeh M, Johnson LA, Heemskerk B <i>et al.<\/i> Tumor antigen\u2013specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114: 1537-1544.","DOI":"10.1182\/blood-2008-12-195792"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Yamamoto R, Nishikori M, Kitawaki T <i>et al.<\/i> PD-1\u2013PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008; 111: 3220-3224.","DOI":"10.1182\/blood-2007-05-085159"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Carbone A, Gloghini A, Cabras A, Elia G. Differentiating germinal center-derived lymphomas through their cellular microenvironment. Am J Hematol. 2009; 84: 435-438.","DOI":"10.1002\/ajh.21434"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol. 2009; 40: 1715-1722.","DOI":"10.1016\/j.humpath.2009.03.025"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin\u2019s lymphoma microenvironment and its role in promoting tumour growth and immune escape. The Journal of Pathology: J Pathol. 2010; 221: 248-263.","DOI":"10.1002\/path.2711"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Adam M, Bekueretsion Y, Abubeker A <i>et al.<\/i> Clinical Characteristics and Histopathological Patterns of Hodgkin Lymphoma and Treatment Outcomes at a Tertiary Cancer Center in Ethiopia. JCO Glob Oncol. 2021; 7: 277-288.","DOI":"10.1200\/GO.20.00391"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Lee D, Xiong S, Xiong WC. General introduction to in situ hybridization protocol using nonradioactively labeled probes to detect mRNAs on tissue sections. Methods Mol Biol. 2013; 1018: 165-174.","DOI":"10.1007\/978-1-62703-444-9_16"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Koelzer VH, Sirinukunwattana K, Rittscher J, Mertz KD. Precision immunoprofiling by image analysis and artificial intelligence. Virchows Arch. 2019; 474: 511-522.","DOI":"10.1007\/s00428-018-2485-z"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Weinreb M, Day PJ, Niggli F <i>et al.<\/i> The consistent association between Epstein-Barr virus and Hodgkin\u2019s disease in children in Kenya. Blood. 1996; 87: 3828-3836.","DOI":"10.1182\/blood.V87.9.3828.bloodjournal8793828"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Enblad G, Sandvej K, Sundstr\u00f6m C, Pallesen G, Glimelius B. Epstein-Barr virus distribution in Hodgkin\u2019s disease in an unselected Swedish population. Acta Oncol. 1999; 38: 425-429.","DOI":"10.1080\/028418699431942"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Trim\u00e8che M, Bonnet C, Korbi S, Boniver J, de Leval L. Association between Epstein-Barr virus and Hodgkin\u2019s lymphoma in Belgium: a pathological and virological study. Leuk Lymphoma. 2007; 48: 1323-1331.","DOI":"10.1080\/10428190701411177"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Ferressini Gerpe NM, Vistarop AG, Moyano A <i>et al.<\/i> Distinctive EBV infection characteristics in children from a developing country. Int J Infect Dis. 2020; 93: 139-145.","DOI":"10.1016\/j.ijid.2020.01.044"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Keresztes K, Miltenyi Z, Bessenyei B <i>et al.<\/i> Association between the Epstein-Barr virus and Hodgkin\u2019s lymphoma in the North-Eastern part of Hungary: effects on therapy and survival. Acta Haematol. 2006; 116: 101-107.","DOI":"10.1159\/000093639"},{"key":"38","unstructured":"38 Cozen W, Katz J, Mack TM. Risk patterns of Hodgkin\u2019s disease in Los Angeles vary by cell type. Cancer Epidemiol Biomarkers Prev. 1992; 1: 261-268."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002; 118: 1071-1077.","DOI":"10.1046\/j.1365-2141.2002.03750.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol. 2011; 2011: 725219.","DOI":"10.1155\/2011\/725219"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Chang KL, Alb\u00fajar PF, Chen YY, Johnson RM, Weiss LM. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin\u2019s disease occurring in Peru. Blood. 1993; 81: 496-501.","DOI":"10.1182\/blood.V81.2.496.bloodjournal812496"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Glaser SL, Jarrett RF. The epidemiology of Hodgkin\u2019s disease. Baillieres Clin Haematol. 1996; 9: 401-416.","DOI":"10.1016\/S0950-3536(96)80018-7"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Nurieva RI, Duong J, Kishikawa H <i>et al.<\/i> Transcriptional regulation of th2 differentiation by inducible costimulator. Immunity. 2003; 18: 801-811.","DOI":"10.1016\/S1074-7613(03)00144-4"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Atayar \u00c7, van den Berg A, Blokzijl T <i>et al.<\/i> Hodgkin\u2019s lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments. J Clin Pathol. 2007; 60: 1092-1097.","DOI":"10.1136\/jcp.2006.044222"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Henry M, Buck S, Sava\u015fan S. Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2018; 65: e27307.","DOI":"10.1002\/pbc.27307"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Men\u00e9ndez V, Sol\u00f3rzano JL, Fern\u00e1ndez S, Montalb\u00e1n C, Garc\u00eda JF. The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good. Cancers (Basel). 2022; 14: 1360.","DOI":"10.3390\/cancers14051360"},{"key":"47","unstructured":"47 Daussy C, Damotte D, Molina TJ <i>et al.<\/i> CD4: CD8 T-cell ratio differs significantly in diffuse large B-cell lymphomas from other lymphoma subtypes independently from lymph node localization. Int Trends Immun. 2013; 1: 45-48."},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Sattarzadeh A, Visser L, Rutgers B, Diepstra A, van den Berg A. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. Int J Mol Sci. 2016; 17: 2127.","DOI":"10.3390\/ijms17122127"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Gunduz E, Sermet S, Musmul A. Peripheral blood regulatory T cell levels are correlated with some poor prognostic markers in newly diagnosed lymphoma patients. Cytometry B Clin Cytom. 2016; 90: 449-454.","DOI":"10.1002\/cyto.b.21330"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Chetaille B, Bertucci F, Finetti P <i>et al.<\/i> Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009; 113: 2765-3775.","DOI":"10.1182\/blood-2008-07-168096"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Duffield AS, Ascierto ML, Anders RA <i>et al.<\/i> Th17 immune microenvironment in Epstein-Barr virus\u2013negative Hodgkin lymphoma: implications for immunotherapy. Blood Adv. 2017; 1: 1324-1334.","DOI":"10.1182\/bloodadvances.2017007260"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Assis MCG, Campos AHFM, Oliveira JSR <i>et al.<\/i> Increased expression of CD4+CD25+FOXP3+ regulatory T cells correlates with Epstein\u2013Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil. Med Oncol. 2012; 29: 3614-3619.","DOI":"10.1007\/s12032-012-0299-4"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Morales O, Mrizak D, Fran\u00e7ois V <i>et al.<\/i> Epstein\u2013Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. Br J Haematol. 2014; 166: 875-890.","DOI":"10.1111\/bjh.12980"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Burdelski C, Jakani-Karimi N, Jacobsen F <i>et al.<\/i> IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncol Rep. 2018; 39: 3-12.","DOI":"10.3892\/or.2017.6072"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Kieser A, Sterz KR. The Latent Membrane Protein 1 (LMP1). Curr Top Microbiol Immunol. 2015; 391: 119-149.","DOI":"10.1007\/978-3-319-22834-1_4"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Liao C, Zhou Q, Zhang Z <i>et al.<\/i> Epstein\u2010Barr virus\u2010encoded latent membrane protein 1 promotes extracellular vesicle secretion through syndecan\u20102 and synaptotagmin\u2010like\u20104 in nasopharyngeal carcinoma cells. Cancer Sci. 2020; 111: 857-868.","DOI":"10.1111\/cas.14305"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Kis LL, Takahara M, Nagy N, Klein G, Klein E. Cytokine mediated induction of the major Epstein\u2013Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett. 2006; 104: 83-88.","DOI":"10.1016\/j.imlet.2005.11.003"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Gandhi MK, Lambley E, Duraiswamy J <i>et al.<\/i> Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen\u2013specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006; 108: 2280-2289.","DOI":"10.1182\/blood-2006-04-015164"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Reichel J, Chadburn A, Rubinstein PG <i>et al.<\/i> Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015; 125: 1061-1072.","DOI":"10.1182\/blood-2014-11-610436"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Taylor JG, Truelove E, Clear A, Calaminici M, Gribben JG. PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion. Haematologica. 2023; 108: 1068-1082.","DOI":"10.3324\/haematol.2022.280014"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/4\/63_23037\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T01:17:51Z","timestamp":1715563071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/4\/63_23037\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23037","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"article-number":"23037"}}